Pancreatic ductal adenocarcinoma (PDAC) is characterized by hypoxic niches that lead to treatment resistance. Therefore, studies of tumor oxygenation and metabolic profiling should contribute to improved treatment strategies. Here we define two imaging biomarkers that predict differences in tumor response to therapy: 1) partial oxygen pressure (pO 2 ), measured by EPR imaging; and 2) [ Collectively, these results demonstrate the ability of molecular imaging biomarkers to predict the response of PDAC to treatment with radiation therapy and TH-302.
Introduction
Pancreatic ductal adenocarcinoma (PDAC), which constitutes 95% of pancreatic cancers, is one of the most aggressive and fatal cancers, with a 5-year survival rate of 5% (1) . As PDAC is so insidious, more than 80% of PDAC cases are already advanced and metastatic when diagnosed, beyond the stage capable of surgical resection (2) .
PDAC is commonly classified as a hypovascular and hypoxic tumor (3) . However, quantitative and non-invasive methods of evaluating oxygenation of this cancer are limited. The only study, to the best of our knowledge, of quantitative oxygen measurement of pancreatic tumors was reported by Koong et al. using the invasive Eppendorf electrode method (4) . The partial oxygen pressure (pO 2 ) in tumors across the 7 patients in this study ranged from 0 to 5.3 mmHg, which is significantly hypoxic compared with the values for a normal pancreas (9.3-92.7 mmHg) (4) . On the other hand, substantial interpatient heterogeneity of the extent of tumor hypoxia was observed.
Matsuo et al. reported the results of a larger scale, but not quantitative, study of oxygen levels in PDAC (5) . In this study, expression of a hypoxia marker, hypoxia-inducible factor 1α (HIF-1α), in PDAC tissues was measured histochemically, and nearly half of the tumors showed non-detectable or low levels of HIF-1α expression. The HIF-1α level was significantly (P=0.035) correlated with poor prognosis. Metran-Nascente et al. reported striking interpatient variation in the hypoxic fraction of tumors in pancreatic cancer patients using a 2-nitroimidazole-based PET tracer, 18 F-fluoroazomycin arabinoside (6) . In their study, the hypoxic fraction ranged widely, from <5% to >50%, and 5 out of 20 evaluable patients did not exhibit any detectable tumor hypoxia.
These reports suggest that not all human pancreatic tumors are hypoxic. Tumor response to treatment in individual patients and the resulting overall survival rate can vary, depending either directly on a tumor's oxygenation status or indirectly on the downstream hypoxia signaling induced 4 by the characteristic hypoxic and acidotic microenvironments. A priori knowledge of these microenvironmental features allows the appropriate choice between anti-proliferative therapies, such as chemotherapeutic, radiation-based modalities for well oxygenated tumors, and hypoxia-activated prodrugs for hypoxic tumors.
Electron paramagnetic resonance imaging (EPRI) is a spectroscopic imaging technique similar to MRI, which is available in preclinical study but not yet applied for human. EPRI detects paramagnetic species that have unpaired electrons such as transition metal complexes and free radicals. With the availability of trityl radical probes as in vivo-compatible paramagnetic tracers, EPRI is being explored for mapping tissue oxygen levels in live animals (7, 8) . The collisional interaction between the oxygen-sensitive tracer and dissolved paramagnetic oxygen leads to a broadening of the spectral line width of the tracer, which linearly correlates with local oxygen concentration, providing quantitative imaging capability of EPRI in determining tissue pO 2 . EPRI has capabilities to provide quantitative maps of tumor pO 2 in preclinical studies (7, 8) , and being evaluated for clinical implementation. On the other hand, hyperpolarized 13 C MRI monitoring of pyruvate metabolism via oxidative phosphorylation or by aerobic glycolysis is a novel metabolic imaging technique which can potentially provide biochemical information related to tumor oxygenation and is already clinically implemented in humans (9) . Cancer cells within hypoxic tumor regions survive by promoting aerobic glycolysis for energy production, where pyruvate is metabolized to lactate by lactate dehydrogenase (LDH). Although the underlying molecular mechanisms of the shift in energy metabolism are complex, diverse, and dependent on the kinds of genomic mutations in individual tumors, the resulting alteration of pyruvate metabolism offers opportunities for non-invasively characterizing tumor physiology and predicting tumor response to particular treatments.
showed quite different response to a hypoxia-activated prodrug TH-302 and the different treatment efficacy was attributed to the difference in tumor oxygenation status which can be artificially modified by a transient hypoxia induction agent (10) . Based on the previous observation, we investigated if two non-invasive imaging biomarkers, pO 2 measured by EPRI and [1-13 C] pyruvate metabolism rate measured by hyperpolarized 13 C MRI, could capture the difference in oxygenation status in three human PDAC xenografts and predict their response to three representative pancreatic cancer treatments, including a first-line chemotherapy, a hypoxia-activated prodrug, and fractionated radiotherapy. control and TH-302 groups in survival analysis were duplicates of our previously published study (10) .
6

Materials and Methods
Human pancreatic xenografts and treatments
EPRI for oxygen imaging
Technical details of the EPR scanner and oxygen image reconstruction were described previously (11) . Parallel coil resonators tuned to 300 MHz were used for EPRI. After the animal was placed in the resonator, an oxygen-sensitive paramagnetic trityl radical probe, OX063 ( diaminobenzidine were used to detect primary antibodies. The stained slides were scanned using a BZ-9000 microscope (Keyence), and the immunostain-positive area was quantified using ImageJ software (downloaded from https://imagej.nih.gov/ij/).
Metabolome analysis
When tumor size was >600 mm 3 , tumor tissues were excised, immediately frozen in liquid nitrogen, and stored at 80 °C until analysis. A total of 116 metabolites involved in glycolysis, the pentose phosphate pathway, the tricarboxylic acid cycle, the urea cycle, and polyamine, creatine, purine, glutathione, nicotinamide, choline, and amino acid metabolism were analyzed using CE-TOF and QqQ mass spectrometry (Carcinoscope Package, Human Metabolome Technologies, Inc., Boston, MA).
Statistical analysis
All of the results are expressed as the means ± SD. The differences in the means of groups were determined by Student's 2-tailed t test. The survival rate was estimated with the Kaplan-Meier survival analysis, where survival rate was defined as tumor volume increasing by <2.5-fold from the original size. The difference between control group and other groups are assessed by the log-rank test. The minimum level of significance was set at p <0.05.
Study approval
All of the animal experiments were performed in compliance with the Guide for the Care and Use of Laboratory Animal Resources (National Research Council, 1996) and were approved by the National Cancer Institute Animal Care and Use Committee (NCI-CCR-ACUC, Bethesda, MD, protocol nos. Figure S1 ), which may contribute to up-regulated glycolysis.
RBB-153, 155, and 159).
Results
Histological and metabolic characterization of three human pancreatic cancer xenografts
EPR oxygen imaging of three human pancreatic cancer xenografts
To investigate the tumor oxygenation levels among the three pancreatic tumors examined, EPR oxygen imaging studies were conducted. T 2 -weighted MR images of the centers of tumors and corresponding 2D slices extracted from 3D EPR oxygen image data set of the PDAC tumors are shown in Fig. 3A and 3B, respectively. Tumor areas were determined using the T 2 -weighted MR images. Quantitative oxygen analysis was performed on the whole tumor area in the 3D oxygen images and histograms of pO 2 distribution of representative tumors are shown in Fig. 3C . The median pO 2 values of the tumors studied were 9.1±1.7, 11.1±2.2, and 17.6±2.6 mmHg, and the corresponding hypoxic tumor fractions (defined as <10 mmHg of oxygen) were 57.7±13.3%, 46.6±7.4%, and 27.3±13.5% for Hs766t, MiaPaCa-2, and Su.86.86 tumors, respectively ( Fig. 3D-E ).
Supplemental Figure S2 shows the representative images of whole mount immunostaining of pimonidazole. The results of quantitative oxygen imaging were consistent with the results of immunostaining and the metabolome analysis, confirming that the PDAC xenografts studied have significant variation in the level of tumor oxygenation. Median pO 2 and HF10 of individual PDAC tumors in EPR oxygen imaging study were listed in supplementary table S1.
Hyperpolarized 13 C MRI of pyruvate metabolism rates in three human pancreatic cancer xenografts
To better understand the metabolic profile of the three PDAC tumor xenograft models, , pyruvate-to-lactate conversion in the tumor region was observed in 13 C MRI scans acquired every 6 second (Fig. 4A) . The pyruvate and lactate signals were plotted, and the conversion rate constant (k pyr-lac ) was calculated based on the plot. Fig.   4B shows how the conversion rate constant k pyr-lac varies across the tumor area and between tumor types. From the data, it can be seen that Hs766t tumors showed the highest k pyr-lac whereas Su.86.86 tumors showed the lowest. As expected, the k pyr-lac was negatively correlated to the tumor pO 2 levels (Fig. 4C ). Lactate to pyruvate ratio and k pyr-lac of individual PDAC tumors in hyperpolarized 13 C MRI study were listed in supplementary table S2.
Treatment responses of three PDAC tumors to chemotherapy and radiotherapy
To further examine the relationship between the oxygenation/aerobic glycolysis profiles and therapeutic effect of anti-cancer therapies, treatment responses to monotherapies and combination therapies of gemcitabine, TH-302, and fractionated radiotherapy on the three PDAC xenograft models were examined in vivo by measuring the tumor size after the treatments. The data for control and TH-302 monotherapy groups in survival analysis were from our previously published study (10 Kaplan-Meier survival curves, in which an end point was set at a tumor volume of 2.5-fold increase from the original size. Figure 5 shows the survival curves of the tumor-bearing mice treated with the monotherapies for three PDAC tumors. Although all tumors had similar survival time without treatment, the responses to the three treatments were significantly different. Supplementary figure S3 shows the plots of tumor growth delay vs. HF10, pO 2 and lac/pyr ratio. The combination therapies containing gemcitabine treatment showed unexpected results. When combined with gemcitabine, oxygen-dependent radiation therapy showed the strongest synergistic effect on the most hypoxic tumor (Hs766t), suggesting a strong radiosensitizing effect by gemcitabine.
Discussion
In the present study, we used two novel molecular imaging techniques, EPR-based pO 2 imaging and hyperpolarized 13 C MRI, to characterize the tumor microenvironment and examine the ability of physiologic and metabolic status to reliably predict the response to three cancer treatment modalities. EPRI can provide a quantitative pO 2 measurement in vivo. As the treatment outcome of radiation therapy or HAPs is known to be closely related to pO 2 in the tumor, oximetry by EPRI is considered to be a useful imaging assessment tool to predict the response to such treatments.
However, due to the limitations of EPRI such as specific absorption rate and lower penetration depth of microwave, it has not been applied in clinical setting. On the other hand, 13 The three PDAC xenograft models were first examined using histological and metabolomic analysis. Histological analysis revealed that Hs766t tumors were hypoxic, hypovascular, and glycolytic, whereas Su.86.86 tumors were less hypoxic, vascular rich, and less glycolytic.
MiaPaCa-2 tumors showed an intermediate profile (Fig. 1) . Metabolomic analyses confirmed the glycolytic profiling of these tumors by showing elevated levels of steady-state metabolites of consistent with glycolysis in Hs766t and MiaPaca-2 tumors (Fig. 2) . Such characterization of PDACs was also non-invasively performed by EPR oximetry and hyperpolarized 13 C MRI of pyruvate. The oxygenation profiles of the three PDAC models obtained from EPR oximetry were consistent with the pimonidazole-positive area in histological analysis (Fig. 1C and Fig. 3D, 3E ) and the metabolic profiles obtained from k pyr-lac in hyperpolarized 13 C MRI (Fig. 4C ) was also consistent with the LDH-positive area in histological analysis (Fig. 1D) . The negative correlation between pO 2 and glycolytic efficiency in PDACs revealed by these imaging modalities suggests a metabolic adaptation represented by activation of hypoxia inducible factors (HIF) that are known to regulate the expression of more than 800 genes. However, the contribution from anaerobic glycolysis to the lactate:pyruvate ratio cannot be separated. Lactate dehydrogenase A and pyruvate dehydrogenase kinase 1 are known to be upregulated by HIF and enhance pyruvate to lactate flux.
The tumor growth experiments showed that the most hypoxic tumor type, Hs766t, showed the longest growth delay (25 ± 7.7 days) upon treatment with the hypoxia-activated pro-drug TH-302
and shortest delay (6.3 ± 2.7 days) after radiation, whereas the least hypoxic tumor type, Su.86.86, showed the shortest delay (0.7 ± 0.6 days) with TH-302 treatment and the longest delay (18.0 ± 2.7 days) after radiation (Fig. 5, Table1 ). This indicates that metabolic profiling by hyperpolarized 13 C MRI as well as tumor oximetry by EPR imaging can potentially serve molecular imaging modalities to predict treatment efficacy of radiation and TH-302 therapies. Gemcitabine monotherapy unexpectedly showed the highest treatment response in Hs766t, the most hypoxic tumor type, although hypoxic tumors are, in general, considered to poorly respond to anti-proliferative chemotherapies (17) (18) (19) . Previous reports have identified proline and glutamine as negatively correlated markers and aspartate, hydroxyproline, creatine, and creatinine as positively correlated markers for gemcitabine resistance in two other human cancer cell lines (20) . In our metabolomic data, the levels of such markers were similar between MiaPaCa-2 tumors and Hs766t tumors and did not predict the differential response to gemcitabine. Further investigations are required to establish whether alterations of metabolites are observed in gemcitabine-resistant PDACs.
Gemcitabine is an anti-metabolite agent which is widely used to treat PDAC tumors.
Gemcitabine is a nucleoside analog in which the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms. Gemcitabine is known to masquerade as a cytidine and get incorporated into new DNA strands, leading to apoptotic cell death. Radiation therapy is known to cause single or double strand breaks in DNA and generate reactive oxygen species (ROS) that inhibit DNA repair. Thus, oxygenated regions in tumors are susceptible to radiation therapy and hypoxic regions are not. On the other hand, TH-302 was developed to selectively target these less perfused hypoxic regions. TH-302 contains a nitroimidazole moiety covalently linked to a bromo-isophosphoramide (Br-IPM) moiety; it undergoes 1-electron reduction followed by unimolecular fragmentation to release the DNA alkylating Br-IPM at low concentrations of oxygen (21) . In vitro studies showed a ~1,000-fold lower IC 50 for cellular cytotoxicity in cells under hypoxia than cells under normoxic conditions (22) .
The treatment responses to combination therapy were also compared with the imaging results. It should be noted that the nitroimidazole moiety of TH-302 is well known to enhance cancer cells to radiation therapy (10, 21) and gemcitabine is reported to enhance the effect of radiation therapy by inhibiting homologous recombination repair even at a low dose (23) . As reported in several previous studies (21, 24, 25) , the combination of radiation and TH-302 resulted in better outcomes than monotherapy in all three PDAC tumor types, presumably by targeting both hypoxic and non-hypoxic regions. The radiosensitizing effect of TH-302 might also potentiate the anti-tumor effects. All gemcitabine-containing combination regimens showed more than additive effects.
Interestingly, a higher synergistic effect of radiation + gemcitabine combination therapy was observed in hypoxic Hs766t tumors than in less hypoxic Su.86.86 tumors (Supplementary Table S1 ).
This was thought to be the result of the radiosensitizing effect of gemcitabine in Hs766t tumors (23) 
Conclusion
In this study, we characterized the tumor microenvironment of three different PDAC xenografts in mice on a metabolic and physiologic basis and obtained imaging biomarkers that were predictive of the differential response to various treatments. The imaging results were consistent with the metabolomic and histologic information obtained from these three xenografts. The imaging data provided useful insight into predicting the treatment efficacy of gemcitabine, TH-302, and radiation, both as monotherapies and combination therapies, in three types of PDAC tumor xenograft models. Tables   Table 1 Treatment Treatment benefit (days) = (days to 2.5 times))-(non-treat)
">" represents the group include mice that survived past 60-day end point. Gem, gemcitabine; XRT, X-radiation therapy. Each group contains 6-9 mice.
Each treatment benefit was compared between tumor types. *, p<0.05; **, p<0.01; ***, p<0.001 (HS, Hs766t; MP, MiaPaca-2, SU, Su.86.86). tumors. The data for control and TH-302 groups in survival analysis were duplicates of our previously published study (10) . See Table 1 for statistical results on treatment benefit. Each treatment group was compared with control group by log-rank test. *, >0.05; **, >0.01; ***, >0.001.
Figure Legends
Fig. 6
Response of three pancreatic tumors to combination therapy. Mice bearing one of three PDAC tumors were treated with a gemcitabine or the following combination therapies: fractionated X-radiation and TH-302, fractionated radiation and gemcitabine, or gemcitabine and TH-302.
Survival" was defined as tumor volume increasing by <2.5-fold from the original size. See Table 1 
